Clinical trials: Anthracycline-induced Cardiac Toxicity
Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy
Some cancer treatments, such as anthracycline chemotherapy and HER2-targeted therapy, can damage the heart (cardiotoxicity). If heart damage is detected early, heart-protective treatment can be started and cancer treatment can…
- Conditions
- Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer, Cardiotoxicity
- Trial name
- SAFE-HEART (NCT07916337)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Skane
Breast Neoplasms
Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
In the context of breast cancer, in case of an indication for chemotherapy, anthracycline-based protocols make it possible to improve the overall survival of patients most at risk.
- Trial name
- SCARA-B (NCT06443645)
- Testing
- Anthracycline
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Paul Strauss
Breast Cancer, Neoplasm, Breast
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020.
- Conditions
- Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents
- Trial name
- NCT05465031
- Testing
- Sacubitril-valsartan
- Where
- 4 sites in Poland
- Volunteers
- 600 people
- Sponsor
- Silesian Centre for Heart Diseases
Early-stage Breast Cancer
Cardioprotective Effect of Acute Exercise in Breast Cancer Patients
Cardiotoxicity is one of the most significant adverse effects in breast cancer patients treated with anthracyclines (a type of chemotherapy), so we propose to determine whether acute training (i.e., 24h before each chemotherapy…
- Trial name
- CardioProtEx (NCT05467111)
- Testing
- Acute Exercise
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Technical University of Madrid
Breast Cancer
Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.
- Trial name
- NCT06491680
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Helwan University
Cardiac Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
The goal of this clinical research study is to learn if certain biomarker testing on blood samples can help to detect heart damage that may occur during chemotherapy.
- Trial name
- NCT01032278
- Testing
- Laboratory Biomarker Analysis, Questionnaires
- Where
- 2 sites in United States
- Volunteers
- 597 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer Therapy-Related Cardiac Dysfunction
Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab
This study aims to evaluate the effectiveness of a cardiac rehabilitation protocol, incorporating aerobic and resistance exercise, in reducing the incidence of cardiotoxicity in breast cancer patients receiving treatment with…
- Trial name
- CARPTOX-BC (NCT06881940)
- Testing
- Rehabilitation Program, No Rehabilitation Program
- Where
- 2 sites in Mexico
- Volunteers
- 284 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Cardiotoxicity, Cardiovascular Disease
Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses
The present study aims to investigate the chronic effect of treatment with doxorubicin and cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant treatment for breast cancer.
- Conditions
- Cardiotoxicity, Cardiovascular Disease, Neurovascular Disorder, Endothelial Disfunction
- Trial name
- NCT04568161
- Testing
- Physical Characteristics, Muscular Sympathetic Nervous Activity, Cardiac Function
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- University of Sao Paulo General Hospital
Cancer and / or Hematological Malignancy, Anthracycline-induced Cardiotoxicity
BHF-COLLATE: UK Prospective, Multi-centre, Observational, Cardio-oncology Anthracycline Registry
The study aims to collect information on how cancer treatment affects heart health. This will include collecting baseline medical information, storing blood samples, recording cancer treatment, and analysing heart scans across…
- Trial name
- BHF-COLLATE (NCT07864467)
- Where
- 6 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- South Tees Hospitals NHS Foundation Trust
Cardiotoxicity
Remote Ischaemic Preconditioning in Childhood Cancer
Survival rates of children with cancers have improved significantly in the recent few decades. Nonetheless, the side effect of this class of drugs on heart function remains to be an issue of concern.
- Trial name
- NCT03166813
- Testing
- Remote Ischaemic Preconditioning, Control
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- The University of Hong Kong
Breast Cancer
Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)
Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom Baker Cancer Centre (TBCC) and included into the study, if they are going to receive chemotherapy with anthracyclines and / or Trastuzumab…
- Trial name
- Cardiotox (NCT00679874)
- Testing
- Cardio-vascular MRI
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University of Calgary
Childhood Cancer
Cardiac 3D MRI in Pediatric Cancer Patients
This is a non-randomized prospective pilot study in a single academic center with historic controls. This study will compare Cardiac Magnetic Resonance Images (MRI) of patients who have undergone childhood cancer treatment that…
- Trial name
- NCT02130934
- Testing
- Cardiac 3D MRI
- Where
- 2 sites in United States
- Sponsor
- Majd Makhoul
DLBCL - Diffuse Large B Cell Lymphoma
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity.
- Trial name
- HO170DLBCL (NCT06220032)
- Testing
- Dexrazoxane, Rituximab, Cyclophosphamide
- Where
- 25 sites in Netherlands
- Volunteers
- 324 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Lymphoma, Heart Failure, Congestive
Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function…
- Trial name
- NCT00195897
- Where
- 2 sites in France
- Volunteers
- 6 people
- Sponsor
- Centre Henri Becquerel
Cardiotoxicity
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
EMPACT (EMPAgliflozin in prevention of chemotherapy-related CardioToxicity) study is a randomized, multi-center, placebo-controlled, double-blind trial to evaluate efficacy of empagliflozin in prevention of left ventricular (LV)…
- Trial name
- EMPACT (NCT05271162)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Poland
- Volunteers
- 220 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Cardiotoxicity, Breast Cancer
Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRCD to…
- Conditions
- Cardiotoxicity, Breast Cancer, Heart Failure
- Trial name
- NCT05298072
- Volunteers
- 180 people
- Sponsor
- University Hospital, Essen
Breast Cancer Female
Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients
According to the European Society of Cardiology 2022, the primary prevention of cancer therapyrelated cardiovascular toxicity during anthracycline chemotherapy include renin-angiotensin- aldosterone system blockers…
- Trial name
- NCT06703593
- Testing
- Alpha lipoic acid
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- British University In Egypt
Cancer, Heart Failure
Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study
Anthracycline (AC) chemotherapy has substantially reduced the mortality rate from several common cancers globally. Unfortunately, AC treatment is associated with up to 19% risk of heart failure (HF).
- Conditions
- Cancer, Heart Failure, Cardiotoxicity
- Trial name
- SPARE-HF (NCT03186404)
- Testing
- Atorvastatin
- Where
- Canada
- Volunteers
- 112 people
- Sponsor
- University Health Network, Toronto
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Aerobic Exercise in Patients Receiving Chemotherapy for Cancer
RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health. PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works…
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00728429
- Testing
- exercise intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the…
- Trial name
- NCT06282796
- Testing
- Echocardiography
- Where
- 5 sites in China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University